JP2021501213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501213A5 JP2021501213A5 JP2020543683A JP2020543683A JP2021501213A5 JP 2021501213 A5 JP2021501213 A5 JP 2021501213A5 JP 2020543683 A JP2020543683 A JP 2020543683A JP 2020543683 A JP2020543683 A JP 2020543683A JP 2021501213 A5 JP2021501213 A5 JP 2021501213A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- dose
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 239000012528 membrane Substances 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000002736 nonionic surfactant Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 229940125379 topical corticosteroid Drugs 0.000 claims 4
- 239000006071 cream Substances 0.000 claims 3
- 239000002674 ointment Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 239000013011 aqueous formulation Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000006343 Cutaneous Mastocytosis Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 206010046740 Urticaria cholinergic Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960004311 betamethasone valerate Drugs 0.000 claims 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 1
- 201000005681 cholinergic urticaria Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 229960004703 clobetasol propionate Drugs 0.000 claims 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 1
- 206010009869 cold urticaria Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960002593 desoximetasone Drugs 0.000 claims 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 201000003158 hyperimmunoglobulin syndrome Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 238000009192 ultraviolet light therapy Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579416P | 2017-10-31 | 2017-10-31 | |
| US62/579,416 | 2017-10-31 | ||
| PCT/CN2018/112714 WO2019085902A1 (en) | 2017-10-31 | 2018-10-30 | Treating ige-mediated allergic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501213A JP2021501213A (ja) | 2021-01-14 |
| JP2021501213A5 true JP2021501213A5 (enExample) | 2021-09-30 |
| JP7286665B2 JP7286665B2 (ja) | 2023-06-05 |
Family
ID=66332803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543683A Active JP7286665B2 (ja) | 2017-10-31 | 2018-10-30 | ＩｇＥ介在アレルギー性疾患の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11439682B2 (enExample) |
| EP (1) | EP3703753A4 (enExample) |
| JP (1) | JP7286665B2 (enExample) |
| KR (1) | KR102859911B1 (enExample) |
| CN (1) | CN111741768B (enExample) |
| AU (1) | AU2018360999A1 (enExample) |
| BR (1) | BR112020008488A2 (enExample) |
| CA (1) | CA3079992A1 (enExample) |
| IL (1) | IL277911B2 (enExample) |
| MX (1) | MX421215B (enExample) |
| TW (1) | TWI821209B (enExample) |
| WO (1) | WO2019085902A1 (enExample) |
| ZA (1) | ZA202002247B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024513039A (ja) * | 2021-04-02 | 2024-03-21 | ワンネス・バイオテック・カンパニー・リミテッド | 高濃度の抗体製剤 |
| CN118119641A (zh) * | 2021-10-12 | 2024-05-31 | 联合生物制药股份有限公司 | Ige调节的疾病的治疗 |
| CN114028731B (zh) * | 2021-12-10 | 2024-01-26 | 固安翌光科技有限公司 | 腰部塑形光疗装置 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514776A (en) | 1987-12-31 | 1996-05-07 | Tanox Biosystems, Inc. | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface |
| US5260416A (en) | 1987-12-31 | 1993-11-09 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted IgE |
| US5089603A (en) | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
| US5252467A (en) | 1987-12-31 | 1993-10-12 | Tanox Biosystems, Inc. | Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE |
| US5342924A (en) | 1987-12-31 | 1994-08-30 | Tanox Biosystems, Inc. | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor |
| US5079344A (en) | 1989-06-21 | 1992-01-07 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted IgA |
| US5362643A (en) | 1989-06-21 | 1994-11-08 | Tanox Biosystems | Antibodies to epitopes present on membrane-bound but not secreted IGA |
| US5614611A (en) | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5231026A (en) | 1987-12-31 | 1993-07-27 | Tanox Biosystems, Inc. | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE |
| US5422258A (en) | 1987-12-31 | 1995-06-06 | Tanox Biosystems, Inc. | Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
| US5254671A (en) | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| US5690934A (en) | 1987-12-31 | 1997-11-25 | Tanox Biosystems, Inc. | Peptides relating to the extracellular membrane-bound segment of human alpha chain |
| US5274075A (en) | 1987-12-31 | 1993-12-28 | Tanox Biosystems, Inc. | Newly identified human epsilon immunoglobulin peptides and related products |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5484907A (en) | 1989-06-21 | 1996-01-16 | Tanox Biosystems, Inc. | Nucleotides coding for the extracellular membrane-bound segment of IgA |
| DE122006000007I2 (de) | 1987-12-31 | 2008-03-27 | Tanox Inc | -tragenden b-lymphocyten befinden. |
| US5292867A (en) | 1988-11-16 | 1994-03-08 | Tanox Biosystems, Inc. | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5310875A (en) | 1989-06-21 | 1994-05-10 | Tanox Biosystems, Inc. | Peptides corresponding to membrane-bound IgA |
| ES2100892T3 (es) | 1989-09-15 | 1997-07-01 | Tanox Biosystems Inc | Tratamiento de enfermedades autoinmunitarias. |
| AU645783B2 (en) | 1990-01-23 | 1994-01-27 | Tanox Biosystems, Inc. | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor |
| US5281699A (en) | 1990-06-01 | 1994-01-25 | Tanox Biosystems, Inc. | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins |
| US5298420A (en) | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
| AU9016591A (en) | 1990-10-25 | 1992-05-26 | Tanox Biosystems, Inc. | Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CA2203165A1 (en) | 1994-10-25 | 1996-05-02 | United Biomedical, Inc. | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy |
| AU3515597A (en) | 1997-05-30 | 1998-12-30 | Tanox Biosystems, Inc. | Inhibition of antigen-specific ige production by antigen coupled to membrane igepetide |
| EP2361635A3 (en) | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| AUPS158502A0 (en) | 2002-04-08 | 2002-05-16 | Dermcare-Vet Pty Ltd | Allergic dermatitis composition and method of treatment |
| US8137670B2 (en) | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
| US20090220416A1 (en) | 2006-05-03 | 2009-09-03 | Sydney Welt | Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders |
| NZ580553A (en) | 2007-03-22 | 2012-05-25 | Genentech Inc | Apoptotic anti- ige antibodies binding the membrane-bound ige |
| KR101529160B1 (ko) * | 2009-02-25 | 2015-06-16 | 아카데미아 시니카 | Ｂ 림프구 상의 인간 ｍＩｇＥ에 결합 가능한 항-ＣεｍＸ 항체 |
| EP2504030A4 (en) * | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011108008A2 (en) | 2010-03-04 | 2011-09-09 | Transgene Biotek Ltd. | Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1 |
| CN104603150A (zh) * | 2012-04-20 | 2015-05-06 | 中央研究院 | 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| JP6068582B2 (ja) * | 2015-08-07 | 2017-01-25 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体 |
-
2018
- 2018-10-30 KR KR1020207014545A patent/KR102859911B1/ko active Active
- 2018-10-30 CA CA3079992A patent/CA3079992A1/en active Pending
- 2018-10-30 JP JP2020543683A patent/JP7286665B2/ja active Active
- 2018-10-30 EP EP18873803.3A patent/EP3703753A4/en active Pending
- 2018-10-30 WO PCT/CN2018/112714 patent/WO2019085902A1/en not_active Ceased
- 2018-10-30 AU AU2018360999A patent/AU2018360999A1/en not_active Abandoned
- 2018-10-30 IL IL277911A patent/IL277911B2/en unknown
- 2018-10-30 MX MX2020004469A patent/MX421215B/es unknown
- 2018-10-30 BR BR112020008488-3A patent/BR112020008488A2/pt unknown
- 2018-10-30 CN CN201880084604.5A patent/CN111741768B/zh active Active
- 2018-10-31 TW TW107138583A patent/TWI821209B/zh active
-
2020
- 2020-04-29 US US16/862,512 patent/US11439682B2/en active Active
- 2020-05-04 ZA ZA2020/02247A patent/ZA202002247B/en unknown
-
2022
- 2022-09-09 US US17/930,799 patent/US12083161B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12454571B2 (en) | Biopharmaceutical compositions | |
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| CN114616249A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| TW202104270A (zh) | 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途 | |
| US11976113B2 (en) | Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins | |
| CN111372948A (zh) | 用il-17拮抗剂治疗化脓性汗腺炎 | |
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2018515493A5 (enExample) | ||
| JP2022188083A (ja) | 化膿性汗腺炎の処置 | |
| JP2021501213A5 (enExample) | ||
| JP2016531123A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| WO2019020069A1 (zh) | 一种sost抗体药物组合物及其用途 | |
| JP2019519584A5 (enExample) | ||
| US20240067716A1 (en) | Ionic liquid formulations for treating inflammatory and autoimmune diseases | |
| IL277911B1 (en) | Treatment of IgE-mediated allergic diseases | |
| WO2022017468A1 (zh) | Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 | |
| Rojas et al. | Role of the animal model on the pharmacokinetics of equine-derived antivenoms | |
| WO2023001228A1 (zh) | 一种抗angptl3抗体或其抗原结合片段的药物组合物及其用途 | |
| CN115551542A (zh) | 抗il-33抗体的配制品 | |
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗ＩＬ－α抗体 | |
| WO2020063668A1 (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| WO2021233408A1 (zh) | 抗α-溶血素的抗体及其稳定制剂 | |
| US20250042985A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) | |
| CN117771379B (zh) | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 | |
| US20240043524A1 (en) | Interleukin 5 binding protein dosage regimen |